



Date: 29th May, 2025

BSE Limited

Dept. of Corporate Services, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001 BSE Scrip Code - 541304

National Stock Exchange of India Limited

Dept. of Corporate Compliances, Exchange Plaza, C-1 Block-G, Bandra Kurla Complex, Bandra (E) Mumbai- 400 051 NSE Symbol: INDOUS

<u>Subject: Annual Secretarial Compliance Report of the Company for the financial year ended on 31st March, 2025 - reg.</u>

Reference: Certificate under Regulation 24A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir(s),

Pursuant to Regulation 24A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the Annual Secretarial Compliance Report for the financial year ended on 31st March, 2025, duly issued by Shri Amrish N. Gandhi, Practising Company Secretary.

Please take the same on record.

Thanking you,

Yours faithfully, For Indo Us Bio-Tech Limited,

DIMPY
DIVYANGBHAI JOSHI
DIVYANGBHAI JOSHI
+05'30'
DIVYANGBHAI JOSHI
Date: 2025.05.29 20:37:09
+05'30'

Ms. Dimpy Joshi

Company Secretary & Compliance Officer

Enclosure: As above



Amrish Gandhi & Associates

Company Secretaries



Secretarial Compliance Report Of INDO US BIO-TECH LIMITED For the financial year ended 31st March, 2025

To,
Indo Us Bio-Tech Limited,
309, Shanti Mall, Satadhar Char Rasta
Opp. Navrang Tower,
Sola Road, Ahmedabad,
Gujarat, India, 380061

I have conducted the review of the compliance of the applicable statutory provisions and the adherence to good corporate practices by Indo Us Bio-Tech Limited (CIN: L01122GJ2004PLC043550) (hereinafter referred as "the listed entity"), having its Registered Office at 309, Shanti Mall, Satadhar Char Rasta Opp. Navrang Tower, Sola Road, Ahmedabad, Gujarat, India, 380061. Secretarial Review was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/ statutory compliances and to provide my observation thereon.

Based on my verification of the listed entity's books, papers, minutes books, forms and returns filed and other records maintained by the listed entity and also the information provided by the listed entity, its officers, agents and authorized representatives during the conduct of Secretarial Review, I hereby report that the listed entity has, during the review period covering the financial year ended on 31st March, 2025, complied with the statutory provisions listed hereunder in the manner and subject to the reporting made hereinafter;

I have examined:

- a. all the documents and records made available to us and explanation provided by Indo Us Bio-Tech Limited ("the listed entity"),
- the filings/ submissions made by the listed entity to the Stock Exchanges,
- c. website of the listed entity,
- any other document/ filing, as may be relevant, which has been relied upon to make this Report,

For the financial year ended 31st March, 2025 ("Review Period") in respect of compliance with the provisions of:

A. the Securities and Exchange Board of India Act, 1992 ("SEBI Act") and the regulations, circulars, guidelines issued thereunder; and

ASCR -Indo Us Bio-Tech Limited-FY 2024-25

Page 1 of 11

504, Shivalik Abaise, Opp. Shell Petrol Pump, Anandnagar Road, Sater amedab.

Phone: 079-40323014, 98256 54756

amrishgandhi72@gmail.com www.agskcs.com

add did

B. the Securities Contracts (Regulation) Act, 1956 ("SCRA"), rules made thereunder and the regulations, circulars, guidelines issued thereunder by the SEBI;

The specific Regulations, whose provisions and the circulars/ guidelines issued thereunder, have been examined, include:-

- Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015;
- b) Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018; - Not Applicable during the review period;
- Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
- d) Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018- Not Applicable during the review period;
- Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 - Not Applicable during the review period;
- Securities and Exchange Board of India (Issue and Listing of Non-Convertible Securities) Regulations, 2021 - Not Applicable during the review period;
- g) Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;

And circulars/ guidelines issued thereunder;

And based on the above examination, I hereby report that, during the Review Period;

a) The listed entity has complied with the provisions of the above Regulations and circulars/ guidelines issued thereunder, except in respect of matters specified below:



s.N	Compliance	Regulation/	Deviations	Actions	Type of	Details of	Fine	Observation	Management	Remarks
0	Requiremen	Circular No.	PART SAME BELLEVIE	taken	Action	Violation	(In Rs.)	by	Response	
	t		The second	by	Advisory/Cl			Practicing		
	(Regulations			3500	arification/		1000	Company		
	/ circulars/				Fine/ Show			Secretary		
	guidelines				Cause					
	including				Notice/					
	specific				Warnings,					
	clauses)				etc.				200000000000000000000000000000000000000	
1.	Regulation 18(1) of SEBI (LODR) Regulations , 2015	Regulation 18(1) of SEBI (LODR) Regulations , 2015	Delay in Compliance	BSE	Fine	The non- compliance was regarding constitution of Audit Committee	Amount Paid: ₹10,800 (includin g GST) (deducti ng TDS)	The company was in non- compliance of Regulation 18(1) of SEBI(Listin g Obligation and Disclosure Requiremen t and for the same company has made wavier application to the NSE	The non- compliance was unintention al and arose due to unforeseen circumstanc es, such as delays in finalizing the appointment of independent directors Despite our efforts to ensure compliance, the timelines could not be adhered to due to procedural challenges.	Wavier applicat on made to the BSE of Rs.122' 20 (Includi g GST)

Page 3 of 11

ASCR - Indo Us Bio-Tech Limited-FY 2024-25

									Immediate corrective actions have been taken to rectify the issue and ensure full compliance with the regulatory requirement 8	
2.	Regulation 18(1) of SEBI (LODR) Regulations , 2015	Regulation 18(1) of SEBI (LODR) Regulations , 2015	Delay in implementa tion	NSE	Fine	The non- compliance for constitution of Audit Committee	Amount Paid: ₹9,440 (includin g GST)	The company was in non- compliance of Regulation 18(1) of SEBI(Listin g Obligation and Disclosure Requiremen t and for the same company has made wavier application to the NSE	The non- compliance was unintention al and arose due to unforeseen circumstanc es, such as Delays in finalizing the appointment of independent directors. Despite our efforts to ensure Compliance, the timelines could not be adhered to due to	Wavier applicati on made to the NSE

ASCR Indo Us Bio-Tech Limited-FY 2024-25

Page 4 of 11
Megaced get

procedural challenges. Immediate corrective actions have been taken to rectify the issue and ensure full compliance with the regulatory
requirement s

b) The listed entity has taken the following actions to comply with the observations made in previous reports:

S.N o	Compliance Requirement (Regulations / circulars/ guidelines including specific	Regulation / Circular No.	Deviation s	Action s taken by	Type of Action Advisory/Clarification / Fine/ Show Cause Notice/ Warnings, etc.	Details of Violatio n	Fine (in Rs.)	Observati on by Practicing Company Secretary	Managemen t Response	Remari
	clauses)									

Not Applicable as no observation was in Previous Report



menerace!

Compliances related to resignation of Statutory Auditors from listed entities and their material subsidiaries as per SEBI Circular CIR/CFD/CMDI/114/2019 dated 18th October, 2019.

Sr. No.	Particulars	Compliance Status Yes/ No/ NA	Observations /Remarks by PCS*
1.	Compliances with the following conditions while appointing/re-appointing an auditor i. If the auditor has resigned within 45 days from the end of a quarter of a financial year, the auditor before such resignation, has issued the limited review/ audit report for such quarter; or ii. If the auditor has resigned after 45 days from the end of a quarter of a financial year, the auditor before such resignation, has issued the limited review/ audit report for such quarter as well as the next quarter; or if the auditor has signed the limited review/ audit report for the first three quarters of a financial year, the auditor before such resignation, has issued the limited review/ audit report for the last quarter of such financial year as well as the audit report for such financial year	NA	Auditor has not resigned during the review period
2.	i. Reporting of concerns by Auditor with respect to the listed entity/ its material subsidiary to the Audit Committee: a. In case of any concern with the management of the listed entity/ material subsidiary such as non-availability of information/ non-cooperation by the management which has hampered the audit process, the auditor has approached the Chairman of the Audit Committee of the listed entity and the Audit Committee shall receive such concern directly and immediately without specifically waiting for the Quarterly Audit Committee meetings. b. In case, the auditor proposes to resign, all concerns with respect to the proposed resignation, along with relevant documents have been brought to the notice of the Audit Committee. In cases where the proposed	NA	Auditor has not resigned during the review period

MANO. FERRO TO CP. NO. 5656

Page 6 of 11

ASCR - Indo Us Bio-Tech Limited- FY 2024-25

me

	resignation is due to non-receipt of information/ explanation from the company, the auditor has informed the Audit Committee the details of information/ explanation sought and not provided by the management, as applicable. c. The Audit Committee/ Board of Directors, as the case may be, deliberated on the matter on receipt of such information from the auditor relating to the proposal to resign as mentioned above and communicate its views to the management and the auditor. ii. Disclaimer in case of non-receipt of information: The auditor has provided an appropriate disclaimer in its audit report, which is in accordance with the Standards of Auditing as specified by ICAI / NFRA, in case where the listed entity/ its material subsidiary has not provided information as required by the auditor.		
3.	The listed entity/ its material subsidiary has obtained information from the Auditor upon resignation, in the format as specified in Annexure-A in SEBI Circular CIR/CFD/CMD 1/114/2019 dated 18th October, 2019.	NA	Auditor has not resigned during the review period



III. I hereby report that, during the Review Period the compliance status of the listed entity is appended as below:

Sr. No.	Particulars	Compliance Status (Yes/No/NA)	Observations /Remarks by PCS
1.	Secretarial Standards: The compliances of the listed entity are in accordance with the applicable Secretarial Standards (SS) issued by the Institute of Company Secretaries India (ICSI), as notified by the Central Government under section 118(10) of the Companies Act, 2013 and mandatorily applicable.	Yes	The listed entity has stated compliance with the applicable Secretarial Standards issued by ICSL However, Minutes of meetings were not properly maintained.
2.	Adoption and timely Updation of the Policies: All applicable policies under SEBI Regulations are adopted with the approval of board of Directors of the listed entity. All the policies are in conformity with SEBI Regulations and has been reviewed & timely updated as per the regulations/circulars/guidelines issued by SEBI.	Yes	
3.	Maintenance and disclosures on Website The listed entity is maintaining a functional website. Timely dissemination of the documents/information under a separate section on the website. Web-links provided in annual corporate governance reports under Regulation 27(2) are accurate and specific which re-	Yes	

ASCR - Indo Us Bio-Tech Limited- FY 2024-25

Page 8 of 11

	Disqualification of Director:		-17
	None of the Director(s) of the listed entity is/ are disqualified under Section 164 of Companies Act, 2013 as confirmed by the listed entity	Yes	
	Details related to Subsidiaries of listed entities have been examined w.r.t.: (a)Identification of material subsidiary companies. (b)Requirements with respect to disclosure of material as well as other subsidiaries.	NA	The Listed entity has no Subsidiaries
	Preservation of Documents: The Listed entity is preserving and maintaining records as prescribed under SEBI Regulations and disposal of records as per Policy of Preservation of Documents and Archival policy prescribed under SEBI (LODR) Regulations, 2015.	Yes	
	Performance Evaluation: The Listed entity has conducted performance evaluation of the Board, Independent Directors and the Committees at the start of every financial year/ during the financial year as prescribed in SEBI Regulations.	Yes	
3.	Related Party Transactions: (a) The Listed entity has obtained prior approval of Audit Committee for all Related party transactions;	Yes	Obtained Prior approval of Audit
	(b) In case no prior approval obtained, the Listed entity shall provide detailed reasons along with confirmation whether the transactions were subsequently	NA	Committee for RPT

	approved/ratified/ rejected by the Audit Committee.		
9.	Disclosure of events or information: The Listed entity has provided all the required disclosure(s) under Regulation 30 along-with Schedule III of SEBI (LODR) Regulations, 2015 within the time limits prescribed thereunder.	Yes	
10.	Prohibition of Insider Trading: The Listed entity is in compliance with Regulation 3(5) & 3(6) SEBI (Prohibition of Insider Trading) Regulations, 2015.	Yes	The listed entity has stated compliance with this regulations. However, the software is not properly updated.
11.	Actions taken by SEBI or Stock Exchange(s), if any: No action(s) has been taken against the listed entity/ its promoters/ directors/ subsidiaries either by SEBI or by Stock Exchanges (including under the Standard Operating Procedures issued by SEBI through various circulars) under SEBI Regulations and circulars/ guidelines issued thereunder except as provided under separate paragraph herein.	No	Non-compliance of Reg. 18(1) of SEBI (LORD) 2015 due to non-adherence to the stipulated requirements. Stock Exchanges have imposed the penalty which was duly paid and for the same Waiver Application was filed to BSE & NSE.
12.	Additional Non-compliances, if any: No additional non-compliances observed for any SEBI regulation/ circular/ guidance note etc. except as reported above.	NA	No additional non- compliances have been observed

M NO. F8193 E W NO. F8193 E CIP. NO. 5659 E

Assumptions & limitation of scope and review:

- Compliance of the applicable laws and ensuring the authenticity of documents and information furnished, are the responsibilities of the management of the listed entity.
- My responsibility is to report based upon our examination of relevant documents and information. This is neither an audit nor an expression of opinion.
- I have not verified the correctness and appropriateness of financial records and books of account of the listed entity.
- 4. This report is solely for the intended purpose of compliance in terms of Regulation 24A (2) of the SEBI (LODR) Regulations, 2015 and is neither an assurance as to the future viability of the listed entity nor of the efficacy or effectiveness with which the management has conducted the affairs of the listed entity.

FOR, AMRISH GANDHI & ASSOCIATES
Practicing Company Secretaries

Place: Ahmedabad Date: 29.05.2025



CS AMRISH N. GANDHI

Proprietor

FCS-8193 | C.P.NO.5656

ICSI Unique Code I2003GJ391700

Peer Review Cert. No. 5814/2024 UDIN number: F008193G000493645